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Abstract 
The role of myeloid-derived suppressor cells (MDSCs) in cancer development has become 
clear over recent years and MDSC targeting is an emerging opportunity for enhancing the 
effectiveness of current anti-cancer therapies. Since MDSCs are not only able to limit anti-
tumour T cell responses, but also to promote tumour angiogenesis and invasion, their 
monitoring has prognostic and predictive value. Herein we review the key features of 
MDSCs in cancer promotion.  
Keywords: myeloid-derived suppressor cells; tumour promotion; immune suppression 
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Myeloid-derived suppressor cells in the tumour microenvironment 
The phenotype of a tumour microenvironment is shaped not only by the epithelial 
component, but also by the interaction with mesenchymal cells and the inflammatory 
infiltrate. In recent years, the contribution of these components to cancer progression has 
been evaluated, including ligands, cell-cell adhesion molecules, metabolites, oxygen and 
multiple soluble factors together with the expansion of immune cells (such as B cells, NK 
cells, macrophages, Th2, Th17 and Treg). Given the prominence of the immune infiltrate in 
the tumour microenvironment, evaluating the so-called “immunoscore” has been proposed 
as a computer-based analysis to quantify the immune component for improved patient 
management [1]. 
 
Myeloid-derived suppressor cells (MDSCs) represent a major population of 
regulatory cells that are expanded in different types of cancer and impair anti-tumour 
innate and adaptive immune responses. Many studies have underscored complex MDSC 
phenotypes that are not restricted to a single defined myeloid cell population, but rather 
exhibit a plastic phenotype responsive to tumour-derived soluble factors. These 
phenotypes can be reduced to three main subsets: granulocytic (PMN)-MDSCs, monocytic 
(M)-MDSCs and early stage (e)-MDSCs [2, 3 and Figure 1]. MDSCs originate from 
myeloid progenitors in the bone marrow and are expanded and activated by stromal and 
tumour-derived factors; the different composition of soluble factors mobilizing MDSCs 
dictates the phenotypical features of MDSC subsets observed in each patient. The 
pathological activation of myeloid precursors causes their acquisition of suppressive 
activity toward immune cells through a number of mechanisms depending on cell-surface 
interactions, the release of short-lived soluble mediators and the activation of enzymes 
(such as PD-L1/2, release of ROS and RNS, and activation of ARG1, IDO, iNOS; reviewed 
in [2]). Besides these strategies of immune suppression, MDSCs are also able to promote 
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tumour growth by acting on cancer cells or by triggering mechanisms responsible for 
tumour dissemination (Figure 1). Here, we will discuss some new advances in the field, 
documenting an enlargement of the sphere of influence of MDSCs.   
 
Direct effects of MDSCs on cancer cells.  
MDSCs may enhance the stemness of cancer cells [4, 5]. In particular, MDSCs triggered 
miRNA101 expression in ovarian cancer cells and promoted cancer stemness by targeting 
corepressor C-terminal-binding protein 2 (CtBP2). High levels of miRNA101 were 
associated with reduced overall survival in ovarian cancer patients; moreover, high CD33+ 
MDSC infiltration correlated with low CtBP2, suggesting that the combination of CtBP2 and 
MDSCs allow for improved prognostic stratification of ovarian cancer [4]. In line with these 
data, STAT-3+ Mo-MDSCs expanded after exposure to human pancreatic cancer (PC) 
cells and increased the frequency of aldehyde dehydrogenase-1+ (ALDH1) cancer stem 
cells; PC patients with a predominant CD14+ tissue infiltrate had reduced survival and the 
CD14+ cell subset correlated with tumour ALDH1 expression [5].  MDSCs may also 
promote tumour progression in PTEN null prostate tumour models by opposing 
senescence of cancer cells through the release of IL-1RA in the tumour microenvironment 
and the consequent effects on IL-1Rα signalling [6]. Of note, IL-1RA inhibited docetaxel-
induced senescence also in human prostate cancer cells, and patients with high levels of 
intratumoural IL-1RA did not respond to docetaxel and had a short disease free survival 
compared with patients with normal IL-1RA, and tumour-infiltrating CD33+ myeloid cells 
were inversely correlated with the presence of p16INK4A+ senescent cells [6].  
 
Promotion of angiogenesis.  
MDSCs may also have a profound influence on tumour angiogenesis; in fact, murine 
MDSCs are not only a rich source of MMP9, which can increase the bioavailability of 
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VEGF, but also have the potential to differentiate into endothelial-like cells [7]. In this 
context, the cytokine Bv8 appears to be an important mediator of myeloid cell mobilization 
and myeloid cell-dependent tumour angiogenesis, since Bv8 expression is upregulated in 
MDSCs following implantation of tumour cells and anti-Bv8 treatment of mice implanted 
with human tumours reduced angiogenesis and tumour growth. Moreover, MDSCs 
mediated tumour refractoriness to bevacizumab, an anti-VEGF neutralizing monoclonal 
antibody, and the molecular mechanisms responsible for resistance to anti-VEGF therapy 
induced by MDSCs reside in the release of cytokines, such as G-CSF and MCP-1 and 
proinflammatory factors MIP-2 and IL-1R [7].  
 
Effects on the pre-metastatic niche.  
There is increasing evidence from preclinical studies that MDSCs play an important role in 
the pre-metastatic niche. An example derived from a spontaneous model of uveal 
melanoma, in which PMN-MDSCs attracted by CXCL5 and infiltrating primary tumours 
were able to actively promote cancer cell dissemination by inducing epithelial-
mesenchymal transition (EMT); transcriptome analysis revealed that the main inducers of 
EMT were Hepatocyte Growth Factor (HGF) and Transforming Growth Factor-β1 (TGF-β1) 
secreted by PMN-MDSCs, and Epidermal Growth Factor (EGF) released by tumour cells 
[8]. In addition, in another spontaneous model of breast cancer, tumour-induced IL-17-
producing γδ T cells drove systemic expansion and polarization of neutrophils to PMN-
MDSCs that, in turn, contributed to suppress a CD8+ response and metastasis formation in 
distant organs [9].  
 
These data indicate that MDSCs, historically recognized as the most potent inhibitors of T 
cell response, are actually able to orchestrate more potent strategies to redefine the 
outcome of tumour development, by contributing to cancer progression and metastasis.  
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Future studies are required to unveil the role of MDSC activity in the pre-metastatic niche 
and provide new immune target therapies to improve metastatic disease management. 
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Legend 
Figure 1. MDSC activity in cancer promotion. Different subsets of MDSCs are recruited 
to the tumor microenvironment and promote tumor progression in several ways: 1) by 
acting directly on tumor cells (upper panel on the right), they can sustain tumor cell 
stemness; 2) through the secretion of pro-angiogenetic factors, thus promoting blood 
vessel formation (central panel on the right); 3) MDSCs support EMT, shown in the lower 
panel on the right. 
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Figure 1. MDSC activity in cancer promotion. Different subsets of MDSCs are recruited to the tumor 
microenvironment and promote tumor progression in several ways: 1) by acting directly on tumor cells 
(upper panel on the right), they can sustain tumor cell stemness; 2) through the secretion of pro-
angiogenetic factors, thus promoting blood vessel formation (central panel on the right); 3) MDSCs support 
EMT, shown in the lower panel on the right.  
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